Status:
COMPLETED
Novel MRI Techniques for the Characterization and Treatment Assessment of High Grade Brain Lesions
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Brain Neoplasm
Lymphoma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This trial studies different magnetic resonance imaging (MRI) techniques and their ability to provide clearer pictures of lesions in patients with high grade brain lesions. An MRI is a type of imaging...
Detailed Description
PRIMARY OBJECTIVES: I. To use 3-dimensional (3D) quantitative mapping to determine whether differences in T2 spin parameters exist between the peritumoral area and normal brain in the contralateral h...
Eligibility Criteria
Inclusion
- At least one enhancing lesion, aggregate of enhancing foci, and nonenhancing lesion measuring at least 1 cm in size and is suspected to be a high grade brain neoplasm
- Patient is dispositioned to surgery, chemotherapy and/or radiation therapy
- Patient is able to understand and give own consent to participate in the study
Exclusion
- Contraindication to magnetic resonance imaging (MRI) as assessed by our standard of care magnetic resonance (MR) screening procedure, which includes implants or devices that are unsafe in the magnetic environment
- Contraindication or history of allergy to Gadolinium-based (gadobutrol \[Gadovist\], gadobenate dimeglumine (Multihance\]) intravenous contrast
- Verbal confirmation of pregnancy or a positive pregnancy test result in patient record
- Prior partial (greater than 50%) or gross total resection of primary tumor
- Prior chemotherapy or radiation treatment to brain
Key Trial Info
Start Date :
January 10 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2022
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT04132843
Start Date
January 10 2020
End Date
September 1 2022
Last Update
November 21 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
M D Anderson Cancer Center
Houston, Texas, United States, 77030